Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Days Payable Outstanding (DPO) 3 year CAGR for the year ending December 31, 2023: -63.63%

Allakos Inc Days Payable Outstanding (DPO) 3 year CAGR is -63.63% for the year ending December 31, 2023. The days payables outstanding ratio measures the average number of days it takes for a company to pay its suppliers. It is calculated by dividing accounts payable by the cost of revenue and then multiplying by 365. This ratio indicates the average payment period for suppliers and reflects the efficiency of managing trade payables. A longer period suggests extended payment terms and potential working capital advantages. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Allakos Inc Days Payable Outstanding (DPO) for the year ending December 31, 2022 was 176.81, a -82.73% change year over year.
Allakos Inc Days Payable Outstanding (DPO) for the year ending December 31, 2021 was 1,024.09, a -52.99% change year over year.
Allakos Inc Days Payable Outstanding (DPO) for the year ending December 31, 2020 was 2,178.45.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends